RBC Capital analyst Luca Issi maintained a Hold rating on Bluebird Bio (BLUE – Research Report) yesterday and set a price target of $14.00. The company's shares closed last Tuesday at $3.85, close to its 52-week low of $3.30. According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of -35.8% and a 7.7% success rate. Issi covers the Healthcare sector, focusing on stocks such as Adverum Biotechnologies, BioMarin Pharmaceutical, and Crispr Therapeutics AG. Bluebird Bio has an analyst consensus of Hold, with a price target consensus of $6.83.
https://www.tipranks.com/news/blurbs/rbc-capital-reaffirms-their-hold-rating-on-bluebird-bio-blue?utm_source=advfn.com&utm_medium=referral
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more bluebird bio Charts.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more bluebird bio Charts.